Investor Presentaiton
Revenue: Major Products in Japan
(Bn JPY)
FY2021 Q1
FY2022 Q1
YOY
Results
Results
Lixiana
anticoagulant
22.9
25.1
+2.2
Tarlige
pain treatment
7.1
8.9
+1.8
Pralia
treatment for osteoporosis/ inhibitor of the progression of
bone erosion associated with rheumatoid arthritis
9.2
9.9
+0.7
Efient
antiplatelet agent
4.1
4.9
+0.7
Tenelia
type 2 diabetes mellitus treatment
6.4
5.6
-0.8
Vimpat
anti-epileptic agent
4.5
5.3
+0.8
Ranmark
treatment for bone complications caused by bone
metastases from tumors
5.1
4.9
-0.2
Canalia
type 2 diabetes mellitus treatment
4.3
4.1
-0.3
Loxonin
anti-inflammatory analgesic
5.8
4.6
-1.2
anti-cancer agent
Enhertu
2.2
2.4
+0.3
(HER2-directed antibody drug conjugate)
Emgality
prophylaxis of migraine attacks
0.9
1.4
+0.6
Daiichi-Sankyo
9View entire presentation